Posttransplant renal allograft dysfunction as a prognostic factor in triple therapy-treated patients.
Pallardó
L M
LM
Nephrology Department, Hospital Universitario La Fe, Valencia, Spain.
García
J
J
Sánchez
J
J
Górriz
J L
JL
Orero
E
E
Calabuig
F
F
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012189:Retrospective Studies; D013997:Time Factors; D014184:Transplantation, Homologous
D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone